prikaz prve stranice dokumenta Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion
  Preuzmi
PDF 1.04 MB
Znanstveni rad - Izvorni znanstveni rad
Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion
European Journal of Pharmaceutical Sciences, 209 (2025); 107077. https://doi.org/10.1016/j.ejps.2025.107077
Ljubica, Josip; Jurišić Dukovski, Bisera; Krtalić, Iva; Juretić, Marina; Safundžić Kučuk, Maša; Petriček, Igor; Špoljarić, Drago; Bočkor, Luka; Kocbek, Petra; Hafner, Anita; Pepić, Ivan; Lovrić, Jasmina

Citirajte ovaj rad

Ljubica, J., Jurišić Dukovski, B., Krtalić, I., Juretić, M., Safundžić Kučuk, M., Petriček, I. ... Lovrić, J. (2025). Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion. European Journal of Pharmaceutical Sciences, 209.. doi: 10.1016/j.ejps.2025.107077

Ljubica, Josip, et al. "Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion." European Journal of Pharmaceutical Sciences, vol. 209, 2025. https://doi.org/10.1016/j.ejps.2025.107077

Ljubica, Josip, Bisera Jurišić Dukovski, Iva Krtalić, Marina Juretić, Maša Safundžić Kučuk, Igor Petriček, Drago Špoljarić, et al. "Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion." European Journal of Pharmaceutical Sciences 209 (2025). https://doi.org/10.1016/j.ejps.2025.107077

Ljubica, J., et al. (2025) 'Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion', European Journal of Pharmaceutical Sciences, 209. doi: 10.1016/j.ejps.2025.107077

Ljubica J, Jurišić Dukovski B, Krtalić I, Juretić M, Safundžić Kučuk M, Petriček I, i sur.. Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion. European Journal of Pharmaceutical Sciences [Internet]. 18.03.2025. [pristupljeno 26.03.2025.];209. doi: 10.1016/j.ejps.2025.107077

J. Ljubica, et al., "Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion", European Journal of Pharmaceutical Sciences, vol. 209, Ožujak 2025. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:163:299551. [Citirano: 26.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:163:299551
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion
AutorJosip Ljubica
AutorBisera Jurišić Dukovski
AutorIva Krtalić
AutorMarina Juretić
AutorMaša Safundžić Kučuk
AutorIgor Petriček
AutorDrago Špoljarić
AutorLuka Bočkor
AutorPetra Kocbek
AutorAnita Hafner
AutorIvan Pepić
AutorJasmina Lovrić
Autorova ustanovaSveučilište u Zagrebu
Farmaceutsko-biokemijski fakultet
(Zavod za farmaceutsku tehnologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Farmacija
Farmacija
Sažetak (engleski)
Loteprednol etabonate (LE) is a soft corticosteroid recently approved for the short-term treatment of signs and symptoms of dry eye disease. LE is available on the market as a suspension, which can release only limited amount of dissolved corticosteroid after application at the ocular surface. This study is focused on the development of an oil-in-water nanoemulsion (NE) to effectively deliver dissolved LE to the ocular surface, in order to promote its absorption. We newly developed an extended-throughput 3D model of the corneal epithelium for biocompatibility study, and an innovative approach to investigate the effect of biorelevant dilution on LE release from the NE oil phase. Castor oil, Capryol® 90, Kolliphor® EL and Soluplus® were selected as NE excipients based on their potential to dissolve LE. Design of experiments was successfully employed to develop biocompatible and physically stable NE with high LE content (0.15 %, w/w) and retention efficiency (87 % after 10 months of storage at room temperature). LE retention within oil droplets (above 90 % of the initial LE content) despite biorelevant dilution simulating tear turnover suggests the potential for direct LE absorption from the NE oil droplets into the lipophilic corneal epithelium. The results obtained encourage the extension of the studies in terms of in vitro permeability and in vivo eye-related bioavailability assessment to prove the potential of the proposed LE formulation.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEuropean Journal of Pharmaceutical Sciences
Brojčani podacivol. 209, 107077
p-ISSN0928-0987
DOIhttps://doi.org/10.1016/j.ejps.2025.107077
URN:NBNurn:nbn:hr:163:299551
Datum objave publikacije2025-03-18
ProjektŠifra: IP-2019-04-2174
Naziv (hrvatski): Nanoemulzije unaprijeđene biofarmaceutske vrijednosti za liječenje bolesti suhoga oka
Naziv (engleski): Biopharmaceutically improved nanoemulsions for the treatment of dry eye disease
Kratica: BeatDED
Voditelj: Jasmina Lovrić
Pravna nadležnost: Hrvatska
Financijer: Hrvatska zaklada za znanost
Linija financiranja: Research Projects
URL dokumentahttps://www.sciencedirect.com/science/article/pii/S0928098725000764?via%3Dihub
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2025-03-26 10:39:30